BioNTech - Ein deutscher Biotech-Riese erwacht (Seite 8006)
eröffnet am 10.10.19 21:59:45 von
neuester Beitrag 04.05.24 10:24:29 von
neuester Beitrag 04.05.24 10:24:29 von
Beiträge: 90.297
ID: 1.313.540
ID: 1.313.540
Aufrufe heute: 55
Gesamt: 8.647.452
Gesamt: 8.647.452
Aktive User: 1
ISIN: US09075V1026 · WKN: A2PSR2 · Symbol: 22UA
86,20
EUR
+0,23 %
+0,20 EUR
Letzter Kurs 03.05.24 Tradegate
Neuigkeiten
02.05.24 · wallstreetONLINE Redaktion |
02.05.24 · inv3st.de Anzeige |
01.05.24 · dpa-AFX |
30.04.24 · kapitalerhoehungen.de Anzeige |
Verhaltene Impfstoff-Nachfrage: BioNTech-Konkurrent Moderna: Umsatz bricht um 91 Prozent einWerte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 38,27 | +28,16 | |
| 8,0780 | +27,90 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 3,6100 | +17,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Wenn man sich den Gesamtmarkt snschaut, ist dieses zarte Minus schon recht gut... Hier füglt man sich als investierter gut aufgehoben
Antwort auf Beitrag Nr.: 65.140.453 von peacepipe am 21.09.20 10:34:29
Nicht einmal $$$ von €€€ unterscheiden können...
Zitat von peacepipe: https://www.lynxbroker.de/boerse/boerse-kurse/aktien/biontech-adr-aktie/biontech-adr-analyse
Nicht einmal $$$ von €€€ unterscheiden können...
MUST READ: "This is a coming-of-age story that you see only every couple of decades in medicine," Arcturus Chief Executive Joseph Payne told IBD.
"The Covid effort absolutely is accelerating the mRNA vaccine field," said ISI Evercore's Miller. "Much of the work absolutely is translatable to further mRNA vaccines."
"The first success for a Covid-19 vaccine will be such a catalyst for the entire class of mRNA," said Robo Global's Deka.
The pandemic brought messenger RNA to the world stage, but mRNA companies for years have taken aim not just at cancers. They've also targeted rare diseases, as well lung and respiratory ailments such as cystic fibrosis, and other infectious illnesses like influenza.
For Coronavirus Stocks, mRNA Potential Is 'Simply Huge'
Now, messenger RNA may be at an inflection point. Frank DeRosa, chief technology officer for Translate Bio, agrees with Payne.
Sure, DeRosa and Payne have an obvious rooting interest in mRNA, but it's easy to find medical investors or analysts who follow coronavirus stocks who are enamored of the technology.
"An exciting, disrupting new class of drug," said Nina Deka, senior research analyst at Robo Global, a Moderna investor.
"MRNA could revolutionize not just the vaccine business but much more," said Brad Loncar, whose Loncar Investments has stakes in Moderna and BioNTech.
"Approval of an mRNA Covid vaccine would be proof-of-concept for mRNA in treating infectious diseases," said Loncar. "It could revolutionize the vaccine business."
"The Covid effort absolutely is accelerating the mRNA vaccine field," said ISI Evercore's Miller. "Much of the work absolutely is translatable to further mRNA vaccines."
"The first success for a Covid-19 vaccine will be such a catalyst for the entire class of mRNA," said Robo Global's Deka.
The pandemic brought messenger RNA to the world stage, but mRNA companies for years have taken aim not just at cancers. They've also targeted rare diseases, as well lung and respiratory ailments such as cystic fibrosis, and other infectious illnesses like influenza.
For Coronavirus Stocks, mRNA Potential Is 'Simply Huge'
Now, messenger RNA may be at an inflection point. Frank DeRosa, chief technology officer for Translate Bio, agrees with Payne.
Sure, DeRosa and Payne have an obvious rooting interest in mRNA, but it's easy to find medical investors or analysts who follow coronavirus stocks who are enamored of the technology.
"An exciting, disrupting new class of drug," said Nina Deka, senior research analyst at Robo Global, a Moderna investor.
"MRNA could revolutionize not just the vaccine business but much more," said Brad Loncar, whose Loncar Investments has stakes in Moderna and BioNTech.
"Approval of an mRNA Covid vaccine would be proof-of-concept for mRNA in treating infectious diseases," said Loncar. "It could revolutionize the vaccine business."
Antwort auf Beitrag Nr.: 65.139.895 von PC-DIDI am 21.09.20 10:06:03
Alle Indices (Dax, Nasdaq, EuroStoxx...) gehen gerade weiter auf Tauchsatation. Von daher BNTX noch relativ OK.
Zitat von PC-DIDI: Der Kurs ist die pure Verhöhnung dieser Aktie. Top News überall und NICHTS passiert!
Alle Indices (Dax, Nasdaq, EuroStoxx...) gehen gerade weiter auf Tauchsatation. Von daher BNTX noch relativ OK.
Trading Spotlight
Antwort auf Beitrag Nr.: 65.139.895 von PC-DIDI am 21.09.20 10:06:03
GEDULD !! 😎☝️
Zitat von PC-DIDI: Der Kurs ist die pure Verhöhnung dieser Aktie. Top News überall und NICHTS passiert!
GEDULD !! 😎☝️
Der Kurs ist die pure Verhöhnung dieser Aktie. Top News überall und NICHTS passiert!
Antwort auf Beitrag Nr.: 65.139.091 von CapCheck33 am 21.09.20 09:25:01👍🏻👏
Antwort auf Beitrag Nr.: 65.139.130 von hueschi am 21.09.20 09:27:08Danke für die Blumen
Antwort auf Beitrag Nr.: 65.139.145 von kleftiko am 21.09.20 09:27:54müsste eigentlich seite 225 des PDF heissen. im Dokument die Seite 223
Durchsuchen
03.05.24 · BörsenNEWS.de · American Express |
03.05.24 · BörsenNEWS.de · Allianz |
02.05.24 · wallstreetONLINE Redaktion · Newron Pharmaceuticals |
01.05.24 · dpa-AFX · Pfizer |
24.04.24 · kapitalerhoehungen.de · Formycon |
22.04.24 · globenewswire · BioNTech |
| Zeit | Titel |
|---|---|
| 21.03.24 | |
| 25.02.24 | |
| 06.11.23 | |
| 29.08.23 |